Willow Tree Research initiates coverage of Silence Therapeutics with a speculative Buy rating, driven by the potential of its mRNAi drug divesiran (SLN124) for treating polycythemia vera (PV). The drug's platform allows infrequent dosing and strong target knockdown, which may differentiate it from competitors. Early Phase 1 data showed promising reductions in phlebotomy and symptom improvements, but confirmation of safety and efficacy is awaited in a pivotal Phase 2 readout expected in August 2026. Despite high clinical and financial risks, the company's discounted valuation and additional drug development opportunities create an attractive risk-reward profile ahead of this key catalyst.
QAIAx Microcities Clinical Trial announced a new patent update for its open-source military-grade AGI platform, QAIAx Cool World, which enables holoportation and hybrid human-AI civic workforce models. The platform supports alternative sentencing and...
The US housing market faces a significant skilled labor shortage, with around 250,000 construction jobs unfilled monthly, slowing homebuilding and increasing costs. This shortage extends construction timelines by nearly two months, inflating prices a...
Evernorth, a major digital asset treasury focused on XRP, has launched a dedicated presence in Japan to capitalize on the country's early adoption and regulatory clarity for XRP. The move aims to strengthen institutional use of XRP in Asia, supported...
Recent crypto scams include fake SecondFi apps designed to steal wallets, a $14.2 million theft of 180,900 Solana tokens from a compromised whale wallet, and a software supply chain attack on the jscrambler npm package distributing malware. These inc...
NNS Holding (Cyprus) Limited announced it purchased 403,642 additional shares of OCI Global N.V. at an average price of €4.08 per share, representing about 0.19% of OCI's issued capital. After this transaction, NNS holds approximately 54.94% of OCI's...
